ALT-01 / Altis Medicines - LARVOL DELTA

First in Human, Randomized, Blinded, Placebo-Controlled Single Ascending Dose Study of ALT-01 in Healthy Participants (clinicaltrials.gov) - P1 | N=50 | Not yet recruiting | Sponsor: Altis Medicines, Inc

First-in-human • New P1 trial • Immunology